$USCTF
Roth CH Acquisition Co. Stock $usctf

$usctf Overview Financials Valuation SEC Filings Company Website

2024 Q3 Form 10-Q Financial Statement

#000182912624007532 Filed on November 14, 2024

Income Statement

Concept	2024 Q3
Revenue
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin
YoY Change
% of Gross Profit
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses
YoY Change
Operating Profit	-$59.86K
YoY Change	-86.99%
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income
YoY Change
Income Tax
% Of Pretax Income
Net Earnings	-$59.86K
YoY Change	-95.28%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share
COMMON SHARES
Basic Shares Outstanding
Diluted Shares Outstanding

Balance Sheet

Concept	2024 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments
YoY Change
Cash & Equivalents	$43.59K
Short-Term Investments
Other Short-Term Assets
YoY Change
Inventory
Prepaid Expenses	$6.375K
Receivables
Other Receivables
Total Short-Term Assets	$49.96K
YoY Change	-70.96%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets	$0.00
YoY Change	-100.0%
TOTAL ASSETS
Total Short-Term Assets	$49.96K
Total Long-Term Assets	$0.00
Total Assets	$49.96K
YoY Change	-99.78%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable
YoY Change
Accrued Expenses
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$1.936M
YoY Change	100.77%
LONG-TERM LIABILITIES
Long-Term Debt
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities	$1.936M
Total Long-Term Liabilities
Total Liabilities	$1.963M
YoY Change	-29.28%
SHAREHOLDERS EQUITY
Retained Earnings	-$8.506M
YoY Change	-16.59%
Common Stock
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$1.913M
YoY Change
Total Liabilities & Shareholders Equity	$49.96K
YoY Change	-99.78%

Cashflow Statement

Concept	2024 Q3
OPERATING ACTIVITIES
Net Income	-$59.86K
YoY Change	-95.28%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities
YoY Change
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities
YoY Change
NET CHANGE
Cash From Operating Activities
Cash From Investing Activities
Cash From Financing Activities
Net Change In Cash
YoY Change
FREE CASH FLOW
Cash From Operating Activities
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2024Q3	USCTU	Forgiveness Of Debt ForgivenessOfDebt		usd
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	001-40959
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	E9
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	98-1601095
	dei	Entity Address City Or Town EntityAddressCityOrTown	Miami Beach
	dei	Entity Address State Or Province EntityAddressStateOrProvince	FL
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	33141
	dei	City Area Code CityAreaCode	(949)
	dei	Local Phone Number LocalPhoneNumber	720-7133
	dei	Amendment Flag AmendmentFlag	false
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2024
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Entity Central Index Key EntityCentralIndexKey	0001860514
CY2024Q3	us-gaap	Preferred Stock Value PreferredStockValue		usd
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2024-09-30
	dei	Entity Registrant Name EntityRegistrantName	ROTH CH ACQUISITION CO.
	dei	Entity Address Address Line1 EntityAddressAddressLine1	2340 Collins Avenue;
	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 402
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
	dei	Entity Shell Company EntityShellCompany	true
CY2024Q3	us-gaap	Cash Cash	43585	usd
CY2023Q4	us-gaap	Cash Cash	13755	usd
CY2023Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	38141	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	51896	usd
CY2023Q4	USCTU	Trust Account Receivable TrustAccountReceivable	147410	usd
CY2023Q4	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments	23332031	usd
CY2024Q3	us-gaap	Assets Assets	49960	usd
CY2024Q3	USCTU	Promissory Note Related Party PromissoryNoteRelatedParty	1109412	usd
CY2023Q4	USCTU	Promissory Note Related Party PromissoryNoteRelatedParty	682508	usd
CY2024Q3	us-gaap	Liabilities Current LiabilitiesCurrent	1936156	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	1343460	usd
CY2024Q3	us-gaap	Extended Product Warranty Accrual ExtendedProductWarrantyAccrual	26700	usd
CY2023Q4	us-gaap	Extended Product Warranty Accrual ExtendedProductWarrantyAccrual	556250	usd
CY2024Q3	us-gaap	Liabilities Liabilities	1962856	usd
CY2023Q4	us-gaap	Liabilities Liabilities	1899710	usd
CY2023Q4	us-gaap	Temporary Equity Value Excluding Additional Paid In Capital TemporaryEquityValueExcludingAdditionalPaidInCapital	23479441	usd
CY2024Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2023Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2024Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	1000000	shares
CY2023Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	1000000	shares
CY2023Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	7107564	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-8955953	usd
CY2024Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	49960	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	23531337	usd
CY2024Q3	us-gaap	Operating Costs And Expenses OperatingCostsAndExpenses	59858	usd
CY2023Q3	us-gaap	Operating Costs And Expenses OperatingCostsAndExpenses	460206	usd
	USCTU	Forgiveness Of Debt ForgivenessOfDebt		usd
CY2024Q3	USCTU	Commitment Fee CommitmentFee		usd
	dei	Document Type DocumentType	10-Q
CY2024Q3	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	6375	usd
CY2024Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-8505598	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	-1847814	usd
	us-gaap	Operating Costs And Expenses OperatingCostsAndExpenses	514632	usd
	us-gaap	Operating Costs And Expenses OperatingCostsAndExpenses	4097406	usd
CY2024Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-59858	usd
CY2023Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-460206	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-514632	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-4097406	usd
CY2023Q3	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	1185925	usd
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-529550	usd
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	1328325	usd
CY2023Q3	us-gaap	Marketable Securities Gain Loss MarketableSecuritiesGainLoss	336709	usd
	us-gaap	Marketable Securities Gain Loss MarketableSecuritiesGainLoss	435437	usd
	us-gaap	Marketable Securities Gain Loss MarketableSecuritiesGainLoss	2204264	usd
CY2023Q3	USCTU	Forgiveness Of Debt ForgivenessOfDebt	42181	usd
	USCTU	Forgiveness Of Debt ForgivenessOfDebt	4692176	usd
	us-gaap	Other Operating Income Expense Net OtherOperatingIncomeExpenseNet	964987	usd
	us-gaap	Other Operating Income Expense Net OtherOperatingIncomeExpenseNet	5443115	usd
CY2024Q3	us-gaap	Net Income Loss NetIncomeLoss	-59858	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	-1267241	usd
	us-gaap	Net Income Loss NetIncomeLoss	450355	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	-1847814	usd
CY2024Q1	USCTU	Remeasurement Of Class Ordinary Shares Subject To Redemption RemeasurementOfClassOrdinarySharesSubjectToRedemption	-485713	usd
CY2024Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	279184	usd
CY2024Q1	us-gaap	Stockholders Equity StockholdersEquity	-2054343	usd
CY2024Q2	USCTU	Remeasurement Of Class Ordinary Shares Subject To Redemption RemeasurementOfClassOrdinarySharesSubjectToRedemption	-29724	usd
CY2024Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	231029	usd
CY2024Q2	us-gaap	Stockholders Equity StockholdersEquity	-1853038	usd
CY2024Q3	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments		usd
CY2024Q3	us-gaap	Temporary Equity Value Excluding Additional Paid In Capital TemporaryEquityValueExcludingAdditionalPaidInCapital		usd
CY2023Q4	us-gaap	Preferred Stock Value PreferredStockValue		usd
CY2024Q3	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants		usd
CY2024Q3	us-gaap	Marketable Securities Gain Loss MarketableSecuritiesGainLoss		usd
CY2023Q3	USCTU	Commitment Fee CommitmentFee		usd
	USCTU	Commitment Fee CommitmentFee		usd
CY2024Q3	us-gaap	Other Operating Income Expense Net OtherOperatingIncomeExpenseNet		usd
CY2024Q3	USCTU	Basic And Diluted Weighted Average Shares Outstanding Class Redeemable Ordinary Shares BasicAndDilutedWeightedAverageSharesOutstandingClassRedeemableOrdinaryShares		shares
CY2024Q3	USCTU	Basic And Diluted Net Loss Income Per Share Class Redeemable Ordinary Shares BasicAndDilutedNetLossIncomePerShareClassRedeemableOrdinaryShares
CY2024Q2	USCTU	Reclassification Of Class Redeemable Shares ReclassificationOfClassRedeemableShares		usd
CY2023Q1	USCTU	Conversion Of Class B Ordinary Shares To Class Ordinary Shares ConversionOfClassBOrdinarySharesToClassOrdinaryShares		usd
CY2023Q2	USCTU	Conversion Of Class B Ordinary Shares To Class Ordinary Shares ConversionOfClassBOrdinarySharesToClassOrdinaryShares		usd
	USCTU	Forgiveness Of Debt ForgivenessOfDebt		usd
	us-gaap	Interest Expense InterestExpense		usd
	USCTU	Increase Decrease In Accrued Offering Costs IncreaseDecreaseInAccruedOfferingCosts		usd
	USCTU	Cash Withdrawn From Trust Account For Working Capital CashWithdrawnFromTrustAccountForWorkingCapital		usd
	USCTU	Trust Receivable TrustReceivable		usd
	USCTU	Advances From Related Party AdvancesFromRelatedParty		usd
	USCTU	Proceeds From Working Capital Advance ProceedsFromWorkingCapitalAdvance		usd
	USCTU	Payment Of Offering Costs PaymentOfOfferingCosts		usd
	USCTU	Conversion Of Advances And Shortterm Promissory Notes To Longterm Promissory Notes ConversionOfAdvancesAndShorttermPromissoryNotesToLongtermPromissoryNotes		usd
	USCTU	Deferred Underwriting Fee Payable Writtenoff DeferredUnderwritingFeePayableWrittenoff		usd
	USCTU	Forgiveness Of Debt From Related Parties ForgivenessOfDebtFromRelatedParties		usd
	dei	Entity Small Business EntitySmallBusiness	true
CY2024Q3	us-gaap	Assets Current AssetsCurrent	49960	usd
CY2024Q3	USCTU	Trust Account Receivable TrustAccountReceivable	-0	usd
CY2023Q4	us-gaap	Assets Assets	23531337	usd
CY2024Q3	us-gaap	Other Accounts Payable And Accrued Liabilities OtherAccountsPayableAndAccruedLiabilities	826744	usd
CY2023Q4	us-gaap	Other Accounts Payable And Accrued Liabilities OtherAccountsPayableAndAccruedLiabilities	660952	usd
CY2024Q3	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2024Q3	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2023Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2023Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2024Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	6592111	usd
CY2024Q3	us-gaap	Stockholders Equity StockholdersEquity	-1912896	usd
	USCTU	Commitment Fee CommitmentFee	-125000	usd
CY2023Q3	us-gaap	Other Operating Income Expense Net OtherOperatingIncomeExpenseNet	-807035	usd
	us-gaap	Net Income Loss NetIncomeLoss	1345709	usd
CY2023Q3	USCTU	Basic And Diluted Weighted Average Shares Outstanding Class Redeemable Ordinary Shares BasicAndDilutedWeightedAverageSharesOutstandingClassRedeemableOrdinaryShares	2337549	shares
	USCTU	Basic And Diluted Weighted Average Shares Outstanding Class Redeemable Ordinary Shares BasicAndDilutedWeightedAverageSharesOutstandingClassRedeemableOrdinaryShares	1051884	shares
	USCTU	Basic And Diluted Weighted Average Shares Outstanding Class Redeemable Ordinary Shares BasicAndDilutedWeightedAverageSharesOutstandingClassRedeemableOrdinaryShares	6403151	shares
CY2023Q3	USCTU	Basic And Diluted Net Loss Income Per Share Class Redeemable Ordinary Shares BasicAndDilutedNetLossIncomePerShareClassRedeemableOrdinaryShares	-0.16
	USCTU	Basic And Diluted Net Loss Income Per Share Class Redeemable Ordinary Shares BasicAndDilutedNetLossIncomePerShareClassRedeemableOrdinaryShares	0.07
	USCTU	Basic And Diluted Net Loss Income Per Share Class Redeemable Ordinary Shares BasicAndDilutedNetLossIncomePerShareClassRedeemableOrdinaryShares	0.11
CY2024Q3	USCTU	Basic And Diluted Weighted Average Shares Outstanding Class And B Nonredeemable Ordinary Shares BasicAndDilutedWeightedAverageSharesOutstandingClassAndBNonredeemableOrdinaryShares	5911553	shares
CY2023Q3	USCTU	Basic And Diluted Weighted Average Shares Outstanding Class And B Nonredeemable Ordinary Shares BasicAndDilutedWeightedAverageSharesOutstandingClassAndBNonredeemableOrdinaryShares	5750000	shares
	USCTU	Basic And Diluted Weighted Average Shares Outstanding Class And B Nonredeemable Ordinary Shares BasicAndDilutedWeightedAverageSharesOutstandingClassAndBNonredeemableOrdinaryShares	5852352	shares
	USCTU	Basic And Diluted Weighted Average Shares Outstanding Class And B Nonredeemable Ordinary Shares BasicAndDilutedWeightedAverageSharesOutstandingClassAndBNonredeemableOrdinaryShares	5750000	shares
CY2024Q3	USCTU	Basic And Diluted Net Loss Income Per Share Class And B Nonredeemable Ordinary Shares BasicAndDilutedNetLossIncomePerShareClassAndBNonredeemableOrdinaryShares	-0.01
CY2023Q3	USCTU	Basic And Diluted Net Loss Income Per Share Class And B Nonredeemable Ordinary Shares BasicAndDilutedNetLossIncomePerShareClassAndBNonredeemableOrdinaryShares	-0.16
	USCTU	Basic And Diluted Net Loss Income Per Share Class And B Nonredeemable Ordinary Shares BasicAndDilutedNetLossIncomePerShareClassAndBNonredeemableOrdinaryShares	0.07
	USCTU	Basic And Diluted Net Loss Income Per Share Class And B Nonredeemable Ordinary Shares BasicAndDilutedNetLossIncomePerShareClassAndBNonredeemableOrdinaryShares	0.11
CY2024Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-59858	usd
CY2024Q3	us-gaap	Stockholders Equity StockholdersEquity	-1912896	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-10482148	usd
CY2023Q1	USCTU	Sale Of Founder Shares And Private Warrant By Sponsor SaleOfFounderSharesAndPrivateWarrantBySponsor	5753	usd
CY2023Q1	USCTU	Sale Of Founder Shares And Private Warrants By Sponsor SaleOfFounderSharesAndPrivateWarrantsBySponsor	-5753	usd
CY2023Q1	USCTU	Capital Contribution From Commitment Fee CapitalContributionFromCommitmentFee	125000	usd
CY2023Q1	USCTU	Remeasurement Of Class Ordinary Shares Subject To Redemption RemeasurementOfClassOrdinarySharesSubjectToRedemption	-1184982	usd
CY2023Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-4671643	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	-16213773	usd
CY2023Q2	USCTU	Reduction Of Deferred Underwriting Fee ReductionOfDeferredUnderwritingFee	8231688	usd
CY2023Q2	USCTU	Capital Contribution From Forgiveness Of Related Party Expenses Note5 CapitalContributionFromForgivenessOfRelatedPartyExpensesNote5	60556	usd
CY2023Q2	USCTU	Capital Contribution From Wejo Assignment And Assumption Agreement Note5 CapitalContributionFromWejoAssignmentAndAssumptionAgreementNote5	250000	usd
CY2023Q2	USCTU	Capital Contribution From Working Capital Advance CapitalContributionFromWorkingCapitalAdvance	250000	usd
CY2023Q2	USCTU	Remeasurement Of Class Ordinary Shares Subject To Redemption RemeasurementOfClassOrdinarySharesSubjectToRedemption	-742574	usd
CY2023Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	7284593	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	-879510	usd
CY2023Q3	USCTU	Remeasurement Of Class Ordinary Shares Subject To Redemption RemeasurementOfClassOrdinarySharesSubjectToRedemption	-456708	usd
CY2023Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-1267241	usd
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	-2603459	usd
	us-gaap	Profit Loss ProfitLoss	450355	usd
	us-gaap	Profit Loss ProfitLoss	1345709	usd
	us-gaap	Marketable Securities Gain Loss MarketableSecuritiesGainLoss	435437	usd
	us-gaap	Marketable Securities Gain Loss MarketableSecuritiesGainLoss	2204264	usd
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-529550	usd
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	1328325	usd
	USCTU	Forgiveness Of Debt ForgivenessOfDebt	4692176	usd
	us-gaap	Interest Expense InterestExpense	125000	usd
	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-31766	usd
	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-255554	usd
	us-gaap	Increase Decrease In Other Accounts Payable And Accrued Liabilities IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities	165792	usd
	us-gaap	Increase Decrease In Other Accounts Payable And Accrued Liabilities IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities	3185207	usd
	USCTU	Increase Decrease In Accrued Offering Costs IncreaseDecreaseInAccruedOfferingCosts	-8000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-317074	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-664645	usd
	USCTU	Investment Of Cash Into Trust InvestmentOfCashIntoTrust	327410	usd
	USCTU	Investment Of Cash Into Trust InvestmentOfCashIntoTrust	180000	usd
	USCTU	Cash Withdrawn From Trust Account For Working Capital CashWithdrawnFromTrustAccountForWorkingCapital	100000	usd
	USCTU	Cash Withdrawn From Trust Account In Connection With Redemption CashWithdrawnFromTrustAccountInConnectionWithRedemption	23994878	usd
	USCTU	Cash Withdrawn From Trust Account In Connection With Redemption CashWithdrawnFromTrustAccountInConnectionWithRedemption	217525458	usd
	USCTU	Trust Receivable TrustReceivable	147410	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	23914878	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	217345458	usd
	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	426904	usd
	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	321941	usd
	USCTU	Advances From Related Party AdvancesFromRelatedParty	310000	usd
	USCTU	Proceeds From Working Capital Advance ProceedsFromWorkingCapitalAdvance	250000	usd
	USCTU	Payment Of Offering Costs PaymentOfOfferingCosts	70000	usd
	USCTU	Redemption Of Ordinary Shares RedemptionOfOrdinaryShares	23994878	usd
	USCTU	Redemption Of Ordinary Shares RedemptionOfOrdinaryShares	217525458	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-23567974	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-216713517	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	29830	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-32704	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	13755	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	124237	usd
CY2024Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	43585	usd
CY2023Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	91533	usd
	USCTU	Conversion Of Advances And Shortterm Promissory Notes To Longterm Promissory Notes ConversionOfAdvancesAndShorttermPromissoryNotesToLongtermPromissoryNotes	91000	usd
	USCTU	Remeasurement Of Class Ordinary Shares Subject To Possible Redemption Amount RemeasurementOfClassOrdinarySharesSubjectToPossibleRedemptionAmount	515437	usd
	USCTU	Remeasurement Of Class Ordinary Shares Subject To Possible Redemption Amount RemeasurementOfClassOrdinarySharesSubjectToPossibleRedemptionAmount	2384264	usd
	USCTU	Deferred Underwriting Fee Payable Writtenoff DeferredUnderwritingFeePayableWrittenoff	8231688	usd
	USCTU	Forgiveness Of Debt From Related Parties ForgivenessOfDebtFromRelatedParties	560556	usd
	us-gaap	Nature Of Operations NatureOfOperations	<p id="xdx_808_eus-gaap--NatureOfOperations_zAgGW1JmRHuf" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 1 — <span id="xdx_820_znZrGqG8pAI7">Description of Organization and Business Operations</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Roth CH Acquisition Co. (the “Company”) is a blank check company incorporated as a Cayman Islands exempted company on April 20, 2021 with the name TKB Critical Technologies 1. The Company changed its name on September 7, 2023 to Roth CH Acquisition Co. The Company was formed for the purpose of entering into a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses (the “initial business combination”).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company is not limited to a particular industry or geographic location for purposes of consummating an initial business combination. The Company is an early stage and emerging growth company and, as such, the Company is subject to all of the risks associated with early stage and emerging growth companies.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of September 30, 2024, the Company had not commenced any operations. All activity for the period from April 20, 2021 (inception) through September 30, 2024, relates to the Company’s formation and its initial public offering (the “IPO”), which is described below and, subsequent to the IPO, identifying a target company for an initial business combination. The Company will not generate any operating revenues until after the completion of the initial business combination, at the earliest. The Company generates non-operating income from the marketable securities held in the Trust Account up to the termination of the Trust Account (defined below).</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The registration statement for the Company’s IPO was declared effective on October 26, 2021 (the “Effective Date”). On October 29, 2021, the Company consummated the IPO of <span id="xdx_905_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20211001__20211029__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_pdd" title="Sale of Stock, Number of Shares Issued in Transaction">23,000,000</span> </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">units (the “Units”), including <span id="xdx_90F_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20211001__20211029__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--OverAllotmentOptionMember_pdd" title="Sale of Stock, Number of Shares Issued in Transaction">3,000,000</span> </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Units that were issued pursuant to the underwriters’ exercise of their over-allotment option in full, at $<span id="xdx_906_eus-gaap--SaleOfStockPricePerShare_c20211029__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_pdd" title="Sale of Stock, Price Per Share">10.00</span> </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">per Unit, generating gross proceeds of $<span id="xdx_909_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_c20211001__20211029__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_pp0p0" title="Sale of Stock, Consideration Received on Transaction">230,000,000</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">, which is discussed in Note 3. Simultaneously with the closing of the IPO, the Company consummated the sale of <span id="xdx_904_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20211001__20211029__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_pdd" title="Sale of Stock, Number of Shares Issued in Transaction">10,750,000</span> </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Private Placement Warrants (the “Private Placement Warrants”) at a price of $<span id="xdx_905_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c20211029__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_pdd" title="Class of Warrant or Right, Exercise Price of Warrants or Rights">1.00</span> </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">per Private Warrant in a private placement to TKB Sponsor I, LLC (the “Sponsor”), generating proceeds of $<span id="xdx_90E_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_c20211001__20211029__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_pp0p0" title="Sale of Stock, Consideration Received on Transaction">10,750,000</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Transaction costs of the IPO amounted to $<span id="xdx_906_ecustom--TransactionCosts_c20211001__20211029_pp0p0" title="Transaction costs">21,140,059</span>, consisting of $<span id="xdx_90A_ecustom--UnderwritingFees_c20211001__20211029_pp0p0" title="Underwriting fees">3,850,000</span> of underwriting discount, $<span id="xdx_90D_ecustom--DeferredUnderwritingFees_c20211001__20211029_pp0p0" title="Deferred underwriting fees">8,800,000</span> of deferred underwriting discount, $<span id="xdx_906_ecustom--ExcessFairValueOfFounderShares_c20211001__20211029_pp0p0" title="Excess fair value of founder shares">7,748,431</span> excess fair value of founder shares and $<span id="xdx_909_ecustom--ActualOfferingCost_c20211001__20211029_pp0p0" title="Actual offering cost">741,628</span> of offering costs. Of these amounts, $<span id="xdx_90D_eus-gaap--AdditionalPaidInCapital_c20211029_pp0p0" title="Additional paid-in capital">19,774,814</span> was recorded to additional paid-in capital and $<span id="xdx_900_ecustom--WarrantLiabilityCost_c20211001__20211029_pp0p0" title="Warrant liability cost">1,365,245</span> costs related to the warrant liability was expensed immediately using the residual allocation method.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Following the closing of the IPO on October 29, 2021, $<span id="xdx_902_eus-gaap--ProceedsFromIssuanceOrSaleOfEquity_c20211001__20211029__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_pp0p0" title="Proceeds from Issuance or Sale of Equity">234,600,000</span> </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">($<span id="xdx_90A_eus-gaap--SharesIssuedPricePerShare_c20211029__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_pdd" title="Shares Issued, Price Per Share">10.20</span> </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">per Unit) from the net proceeds of the sale of the Units in the IPO and the sale of the Private Placement Warrants was placed in a trust account (the “Trust Account”), located in the United States, which were invested in U.S. government securities, within the meaning set forth in Section 2(a)(16) of the Investment Company Act, with a maturity of 185 days or less or in any open-ended investment company that holds itself out as a money market fund selected by the Company meeting the conditions of Rule 2a-7 of the Investment Company Act, as determined by the Company, until the earlier of: (i) the completion of an initial business combination; and (ii) the redemption of any Public Shares (as defined below) properly submitted in connection with a shareholder vote to amend the Company’s Amended and Restated Memorandum and Articles of Association (“Articles”); and (iii) the redemption of the Company’s Public Shares if the Company is unable to complete the initial business combination by October 29, 2024 (or any extended period of time that the Company may have to consummate an initial business combination as a result of an amendment to its Articles) (the “Combination Period”). On April 29, 2024, pursuant to the Third Amendment, as described below, the Trust Account was voluntarily liquidated and the provisions in the Articles requiring that an initial business combination be completed within the Combination Period and other SPAC-related provisions (collectively, the “SPAC Provisions”) were eliminated.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Prior to the effectiveness of the Third Amendment, the Company’s management has broad discretion with respect to the specific application of the net proceeds of the IPO and the sale of the Private Placement Warrants, although substantially all of the net proceeds are intended to be applied generally toward consummating an initial business combination. There is no assurance that the Company will be able to complete an initial business combination successfully. Prior to the effectiveness of the Third Amendment, the Company was required to complete an initial business combination with one or more operating businesses or assets that together have an aggregate fair market value equal to at least 80% of the net assets held in the Trust Account (excluding the deferred underwriting commissions and taxes payable on the income earned on the Trust Account) at the time of the Company’s signing a definitive agreement in connection with its initial business combination and could only complete an initial business combination if the post-transaction company owned or acquired 50% or more of the outstanding voting securities of the target or otherwise acquired an interest in the target business or assets sufficient for it not to be required to register as an investment company under the Investment Company Act of 1940, as amended (the “Investment Company Act”).</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Prior to the effectiveness of the Third Amendment, the Company was required to provide its holders of the outstanding Public Shares (the “public shareholders”) with the opportunity to redeem all or a portion of their Public Shares upon the completion of an initial business combination either (i) in connection with a general meeting called to approve the initial business combination or (ii) by means of a tender offer. The decision as to whether the Company will seek shareholder approval of an initial business combination or conduct a tender offer will be made by the Company. The public shareholder will be entitled to redeem their Public Shares for a pro rata portion of the amount then in the Trust Account ($10.20 per Public Share initially, plus any pro rata interest earned on the funds held in the Trust Account and not previously released to the Company to pay its tax obligations and which interest shall be net of taxes payable), calculated as of two business days prior to the completion of the initial business combination. There will be no redemption rights upon the completion of an initial business combination with respect to the Company’s warrants. In connection with the approval of the Third Amendment to remove the SPAC Provisions, the Company revised the Articles to allow shareholders of the Company to obtain their pro rata distribution of funds held in the Trust Account and also retain ten (10%) percent of their shares upon liquidation of the Trust Account.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On January 10, 2023, the Company, entered into a business combination agreement with Wejo Group Limited, an exempted company limited by shares incorporated under the laws of Bermuda (“Wejo”), and Green Merger Subsidiary Limited, an exempted company incorporated under the laws of the Cayman Islands and a direct, wholly owned subsidiary of Wejo (“Merger Sub 1”) and upon execution of a joinder to the business combination agreement, each of Wejo Holdings Limited, an exempted company limited by shares incorporated under the laws of Bermuda and a wholly owned subsidiary of Wejo (“Holdco”) and Wejo Acquisition Company Limited, an exempted company limited by shares incorporated under the laws of Bermuda and a wholly owned Subsidiary of Holdco (“Merger Sub 2” and together with Merger Sub 1) (as it may be amended, restated, supplemented or otherwise modified from time to time, the “Business Combination Agreement”). On June 25, 2023, the Company, Wejo, Holdco, Merger Sub 1 and Merger Sub 2 entered into that certain Mutual Termination Agreement (“Termination Agreement”) pursuant to which the parties mutually agreed to terminate the Business Combination Agreement pursuant to Section 7.1(a) thereof. The Termination Agreement also includes mutual releases of the parties. No party will be required to pay a termination fee as a result of the mutual decision to enter into the Termination Agreement. The termination of the Business Combination Agreement also terminates the Voting Agreement, dated as of January 10, 2023 (“Wejo Voting Agreement”) between the Company and certain shareholders of Wejo and the Voting Agreement, dated as of January 10, 2023 (the “Sponsor Voting Agreement”) between the Company, Sponsor and Directors, pursuant to the terms of the Wejo Voting Agreement and Sponsor Voting Agreement, respectively.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On January 27, 2023, the Company held an extraordinary general meeting (the “Extraordinary General Meeting”). At the Extraordinary General Meeting, the shareholders approved a proposal (the “Extension Amendment Proposal”) to amend the Company’s Amended and restated memorandum and articles of association (the “Articles”) to extend the date that the Company has to consummate a business combination from January 29, 2023 to June 29, 2023 (the “Extension Amendment”). The shareholders also approved a proposal (the “Trust Agreement Amendment Proposal”) to amend the Company’s Investment Management Trust Agreement, dated as of October 26, 2021, by and between the Company and Continental Stock Transfer & Trust Company as trustee (the “Trust Agreement”), to make a corresponding extension to the date the Company must commence liquidation of the Trust Account from January 29, 2023, to June 29, 2023. In connection with the vote to approve the Extension Amendment Proposal, the holders of <span id="xdx_90F_ecustom--ClassOrdinaryShares_c20230127_pdd" title="Class A ordinary shares">17,533,296</span> Class A ordinary shares properly exercised their right to redeem their shares for cash at a redemption price of approximately $<span id="xdx_90E_ecustom--OrdinaryStockRedemptionPricePerShare_c20230127_pdd" title="Redemption price">10.38</span> per share, for an aggregate redemption amount of approximately $<span id="xdx_900_ecustom--AggregateRedemptionAmount_iI_pn3n3_dm_c20230127_z2K8Usa1XP7k" title="Aggregate redemption amount">181.9</span> million.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On June 25, 2023, the Company, the Sponsor, each independent director of the Company (the “Directors”), and affiliates of Roth Capital Partners and Craig-Hallum Capital Group LLC (the “Buyers”) entered into a Securities Transfer Agreement (the “Agreement”) pursuant to which Sponsor and the Directors have agreed to sell to Buyers, and Buyers have agreed to purchase from Sponsor and the Directors, an aggregate of <span id="xdx_90A_ecustom--ClassOrdinaryShares_c20230625_pdd" title="Class A ordinary shares">4,312,500</span> ordinary shares consisting of <span id="xdx_90E_ecustom--ClassOrdinaryShares_c20230625__us-gaap--StatementEquityComponentsAxis__custom--ClassAOrdinarySharesMember_pdd" title="Class A ordinary shares">4,237,500</span> Class A ordinary shares and <span id="xdx_909_ecustom--ClassOrdinaryShares_c20230625__us-gaap--StatementEquityComponentsAxis__custom--ClassBOrdinarySharesMember_pdd" title="Class A ordinary shares">75,000</span> Class B ordinary shares and <span id="xdx_908_eus-gaap--ClassOfWarrantOrRightOutstanding_c20230625_pdd" title="Class of warrant or right, outstanding">8,062,500</span> private placement warrants (together, the “Transferred Securities”) for an aggregate purchase price (the “Purchase Price”) of $<span id="xdx_904_eus-gaap--SharePrice_c20230625_pdd" title="Share price">1.00</span> (the “Transaction”). Following the closing of the Transaction, Sponsor will have certain continuing rights, including a right of first refusal to repurchase the Transferred Securities in certain circumstances as set forth in the Agreement and the right to invest up to 25% of certain financings. The closing of the Transaction is conditioned upon, among other things, (i) the termination of the Business Combination Agreement (as noted above) and the complete release of actual or potential claims or liabilities thereunder, (ii) continued listing of the Company’s Class A ordinary shares on Nasdaq, (iii) the waiver by the underwriters of the Company’s initial public offering of their rights to deferred underwriting compensation pursuant to the Underwriting Agreement dated as of October 26, 2021, between the Company and Jefferies LLC as representative of the underwriters named therein, and (iv) the occurrence of the Class B Conversion.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On June 26, 2023, the Company entered into a termination agreement (the “Termination Agreement”), pursuant to which the Company terminated the Administrative Services Agreement with Tartavull Klein Blatteis Capital, LLC dated October 26, 2021 and Tartavull Klein Blatteis Capital, LLC forgave and fully discharged all outstanding fees thereunder as of the date of the Closing.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On June 28, 2023, the Company held an extraordinary general meeting (the “Second Extraordinary General Meeting”). At the Extraordinary General Meeting, the shareholders approved a proposal (the “Second Extension Amendment Proposal”) to amend the Company’s Amended and restated memorandum and articles of association (the “Articles”) to extend the date that the Company has to consummate a business combination from June 29, 2023 to October 29, 2024 (the “Extension Amendment”). The shareholders also approved a proposal (the “Second Trust Agreement Amendment Proposal”) to amend the Company’s Trust Agreement, to make a corresponding extension to the date by which the Trustee is obligated to liquidate the trust account to the later of (A) June 29, 2023 provided that the Company may extend such date, monthly, up to October 29, 2024 (i.e.: 36 months after the closing of the IPO provided that the Sponsor or its designee deposits the Monthly Deposit (as defined below) into the trust account), or (B) such later date as may be approved by the Company’s shareholders in accordance with the Company’s amended and restated memorandum and articles of association. The term “Monthly Deposit” is defined in the Amendment to mean an amount equal to the lesser of (x) $<span id="xdx_906_eus-gaap--Deposits_c20230628_pp0p0" title="Aggregate deposit">60,000</span> or (y) $0.03 per public share multiplied by the number of public shares outstanding. In connection with the vote to approve the Second Extension Amendment Proposal, the holders of <span id="xdx_909_ecustom--ClassOrdinaryShares_c20230628_pdd" title="Class A ordinary shares">3,347,468</span> Class A ordinary shares properly exercised their right to redeem their shares for cash at a redemption price of approximately $<span id="xdx_901_ecustom--OrdinaryStockRedemptionPricePerShare_c20230628_pdd" title="Redemption price">10.64</span> per share, for an aggregate redemption amount of approximately $<span id="xdx_909_ecustom--AggregateRedemptionsAmount_iI_pp0p0_c20230628_zUCTYp6Eb2Rc" title="Aggregate redemptions amount">35,601,649</span>. These shares were effectively canceled on July 7, 2023.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On each of January 5, 2024, February 6, 2024, and March 6, 2024, the Company deposited an additional $<span id="xdx_904_ecustom--AdditionalDeposit_iI_pp0p0_c20240105_zBRGXCrF5sg4" title="Additional deposit"><span id="xdx_908_ecustom--AdditionalDeposit_iI_pp0p0_c20240206_zx7M1REWVYqd" title="Additional deposit"><span id="xdx_908_ecustom--AdditionalDeposit_iI_pp0p0_c20240306_zc51rRoBEl72" title="Additional deposit">60,000</span></span></span>, for an aggregate of $<span id="xdx_90E_ecustom--AggregateAmount_iI_pp0p0_c20240105_zDQ1u7JzLFE3" title="Aggregate amount"><span id="xdx_906_ecustom--AggregateAmount_iI_pp0p0_c20240206_z6dJNbNThazd" title="Aggregate amount"><span id="xdx_901_ecustom--AggregateAmount_iI_pp0p0_c20240306_zlB6S0QHk8qc" title="Aggregate amount">180,000</span></span></span>, into the trust extending the date of which the Company has to complete a Business Combination to March 29, 2024.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On February 29, 2024, Gordon Roth resigned as Chief Financial Officer of the Company and the Board appointed Joseph Tonnos as Chief Financial Officer of the Company, effective February 29, 2024. Mr. Roth’s decision to resign was not the result of any dispute or disagreement with the Company or any matter relating to the Company’s operations, policies or practices.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On April 3, 2024, the Overpayment Amount, as described in Note 8, was deposited back into Trust Account.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On April 15, 2024, Roth CH Acquisition Co. (the “Company”) announced that it had notified the Nasdaq Stock Market LLC (“Nasdaq”) of its decision to voluntarily delist its Class A Ordinary Shares, Units and Warrants exercisable for one Class A Ordinary Share at an exercise price of $<span id="xdx_90D_ecustom--OrdinarySharesExercisePrice_iI_c20240415_z3kPPTLIzMBa" title="Ordinary shares exercise price">11.50</span> from the Nasdaq Global Market. The Company filed a Form 25 with the Securities and Exchange Commission (the “SEC”) to remove its Class A Ordinary Shares, Units, and Warrants from listing on the Nasdaq Global Market on April 25, 2024 and as a result, the delisting became effective on April 25, 2024. The Company remains subject to such reporting obligations under Sections 13 and 15(d) of the Exchange Act. Following the delisting, the Company has its Class A Ordinary Shares, Units, and Warrants quoted on a market operated by OTC Markets Group Inc. (the “OTC”) so that a trading market may continue to exist for such securities.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On April 29, 2024, the shareholders approved the amendment of the Articles of Association (“Third Amendment”). The Third Amendment reflects the removal of the provisions contained in the Articles that are applicable to special purpose acquisition companies (“SPACs”), including the requirement to redeem and cancel 100% of the Company’s Public Shares following distribution of the funds held in the Company’s trust account established in connection with the IPO. In connection with the implementation of the Third Amendment, the Company redeemed 90% of the Public Shares and provided each holder their pro rata share of the balance in the Trust Account. The trust liquidation was effective May 15, 2024.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Liquidity and Going Concern</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of September 30, 2024, the Company had $<span id="xdx_907_eus-gaap--Cash_pp0p0_c20240930_ziMKZgEK5uk3" title="Cash">43,585</span> cash and a working capital deficit of $<span id="xdx_907_ecustom--WorkingCapitalDeficit_pp0p0_c20240930_zP1K84pfvTu2" title="Working capital deficit">1,886,196</span>. The Company has incurred and expects to continue to incur significant costs in pursuit of its financing and acquisition plans. The Company expects that it will need to raise additional capital through loans or additional investments from its Sponsor, shareholders, officers, directors or third parties. The Company’s officers, directors and Sponsor may, but are not obligated to, loan the Company funds, from time to time or at any time, in whatever amount they deem reasonable in their sole discretion, to meet the Company’s working capital needs. Accordingly, the Company may not be able to obtain additional financing. If the Company is unable to raise additional capital, it may be required to take additional measures to conserve liquidity, which could include, but not necessarily be limited to, curtailing operations, suspending the pursuit of a potential transaction, and reducing overhead expenses. The Company cannot provide any assurance that new financing will be available to it on commercially acceptable terms, if at all. These conditions raise substantial doubt about the Company’s ability to continue as a going concern. The condensed financial statements do not include any adjustments that might result from the outcome of this uncertainty.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On April 29, 2024, the shareholders approved the amendment of the Articles of Association (“Third Amendment”). The Third Amendment reflects the removal of the provisions contained in the Articles that are applicable to special purpose acquisition companies (“SPACs”), including the requirement to redeem and cancel 100% of the Company’s Public Shares following distribution of the funds held in the Company’s trust account established in connection with the IPO. In connection with the implementation of the Third Amendment, the Company redeemed 90% of the Public Shares and provided each holder their pro rata share of the balance in the Trust Account.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company assessed going concern considerations in accordance with Financial Accounting Standard Board’s Accounting Standards Codification (“<span style="text-decoration: underline">ASC</span>”) Topic 205-40, “Basis of Presentation – Going Concern”. Management has determined that the liquidity condition raises substantial doubt about the Company’s ability to continue as a going concern. No adjustments have been made to the carrying amounts of assets or liabilities.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Risks and Uncertainties</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management continues to evaluate the impact of the COVID-19 pandemic and has concluded that while it is reasonably possible that the virus could have a negative effect on the Company’s financial position, results of its operations, and/or search for a target company, the specific impact is not readily determinable as of the date of these condensed financial statements. The condensed financial statements does not include any adjustments that might result from the outcome of this uncertainty.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In February 2022, the Russian Federation and Belarus commenced a military action with the country of Ukraine. As a result of this action, various nations, including the United States, have instituted economic sanctions against the Russian Federation and Belarus. Further, the impact of this action and related sanctions on the world economy are not determinable as of the date of these condensed financial statements. The specific impact on the Company’s financial condition, results of operations and cash flows is also not determinable as of the date of these condensed financial statements.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p>
CY2021Q4	USCTU	Transaction Costs TransactionCosts	21140059	usd
CY2021Q4	USCTU	Underwriting Fees UnderwritingFees	3850000	usd
CY2021Q4	USCTU	Deferred Underwriting Fees DeferredUnderwritingFees	8800000	usd
CY2021Q4	USCTU	Excess Fair Value Of Founder Shares ExcessFairValueOfFounderShares	7748431	usd
CY2021Q4	USCTU	Actual Offering Cost ActualOfferingCost	741628	usd
CY2021Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	19774814	usd
CY2021Q4	USCTU	Warrant Liability Cost WarrantLiabilityCost	1365245	usd
CY2023Q1	USCTU	Class Ordinary Shares ClassOrdinaryShares	17533296	shares
CY2023Q1	USCTU	Ordinary Stock Redemption Price Per Share OrdinaryStockRedemptionPricePerShare	10.38
CY2023Q1	USCTU	Aggregate Redemption Amount AggregateRedemptionAmount	181900000	usd
CY2023Q2	USCTU	Class Ordinary Shares ClassOrdinaryShares	4312500	shares
CY2023Q2	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	8062500	shares
CY2023Q2	us-gaap	Share Price SharePrice	1.00
CY2023Q2	us-gaap	Deposits Deposits	60000	usd
CY2023Q2	USCTU	Class Ordinary Shares ClassOrdinaryShares	3347468	shares
CY2023Q2	USCTU	Ordinary Stock Redemption Price Per Share OrdinaryStockRedemptionPricePerShare	10.64
CY2023Q2	USCTU	Aggregate Redemptions Amount AggregateRedemptionsAmount	35601649	usd
CY2024Q1	USCTU	Additional Deposit AdditionalDeposit	60000	usd
CY2024Q1	USCTU	Additional Deposit AdditionalDeposit	60000	usd
CY2024Q1	USCTU	Additional Deposit AdditionalDeposit	60000	usd
CY2024Q1	USCTU	Aggregate Amount AggregateAmount	180000	usd
CY2024Q1	USCTU	Aggregate Amount AggregateAmount	180000	usd
CY2024Q1	USCTU	Aggregate Amount AggregateAmount	180000	usd
CY2024Q2	USCTU	Ordinary Shares Exercise Price OrdinarySharesExercisePrice	11.50
CY2024Q3	us-gaap	Cash Cash	43585	usd
CY2024Q3	USCTU	Working Capital Deficit WorkingCapitalDeficit	1886196	usd
	us-gaap	Use Of Estimates UseOfEstimates	<p id="xdx_849_eus-gaap--UseOfEstimates_zJYR4AiNx291" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_865_zRBNPGykbXUb">Use of Estimates</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of the condensed financial statements in conformity with GAAP requires the Company’s management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed financial statements and the reported amounts of revenues and expenses during the reporting period.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the condensed financial statements, which management considered in formulating its estimate, could change in the near term due to one or more future confirming events. One of the more significant accounting estimates included in these condensed financial statements is the determination of the fair value of the warrant liabilities. Such estimates may be subject to change as more current information becomes available. Accordingly, the actual results could differ significantly from those estimates.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2024Q3	us-gaap	Cash Cash	43585	usd
CY2023Q4	us-gaap	Cash Cash	13755	usd
CY2024Q3	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	0	usd
CY2023Q4	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	0	usd
CY2021Q4	USCTU	Transaction Cost TransactionCost	21140059	usd
CY2021Q4	USCTU	Underwriting Fees UnderwritingFees	3850000	usd
CY2021Q4	USCTU	Deferred Underwriting Fees DeferredUnderwritingFees	8800000	usd
CY2021Q4	USCTU	Excess Fair Value Of Founder Shares ExcessFairValueOfFounderShares	7748431	usd
CY2021Q4	USCTU	Actual Offering Costs ActualOfferingCosts	741628	usd
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	1365245	usd
CY2021Q4	USCTU	Additional Paid In Capitals AdditionalPaidInCapitals	19774814	usd
	us-gaap	Derivatives Reporting Of Derivative Activity DerivativesReportingOfDerivativeActivity	<p id="xdx_847_eus-gaap--DerivativesReportingOfDerivativeActivity_zGDh8cZT7ife" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_861_znmkNhjxLnTf">Derivative Financial Instruments</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company evaluates its financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded derivatives in accordance with ASC Topic 815, “Derivatives and Hedging.” For derivative financial instruments that are accounted for as liabilities, the derivative instrument is initially recorded at its fair value on the grant date and is then re-valued at each reporting date, with changes in the fair value reported in the condensed statements of operations. The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is evaluated at the end of each reporting period. Derivative liabilities are classified in the balance sheet as current or non-current based on whether or not net-cash settlement or conversion of the instrument could be required within 12 months of the balance sheet date.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p>
CY2024Q3	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	0	usd
CY2023Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	0	usd
CY2024Q3	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	0	usd
CY2023Q4	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	0	usd
CY2021Q4	us-gaap	Sale Of Stock Number Of Shares Issued In Transaction SaleOfStockNumberOfSharesIssuedInTransaction	22250000	shares
	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p id="xdx_84A_eus-gaap--ConcentrationRiskCreditRisk_zfF6JnBqnT9e" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86F_z0U6jzsoqvl4">Concentration of Credit Risk</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial instruments that potentially subject the Company to concentrations of credit risk consist of a cash account in a financial institution, which, at times, may exceed the Federal Depository Insurance Corporation coverage of $<span id="xdx_904_eus-gaap--FederalFundsSold_iI_pp0p0_c20240930_zCl3tN81d9D9" title="Federal Depository Insurance Coverage">250,000</span>. The Company has not experienced losses on this account.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2024Q3	us-gaap	Federal Funds Sold FederalFundsSold	250000	usd
CY2021Q4	USCTU	Transaction Costs TransactionCosts	21140059	usd
CY2021Q4	USCTU	Underwriting Fees UnderwritingFees	3850000	usd
CY2021Q4	USCTU	Deferred Underwriting Fees DeferredUnderwritingFees	8800000	usd
CY2021Q4	USCTU	Excess Fair Value Of Founder Shares ExcessFairValueOfFounderShares	7748431	usd
CY2021Q4	USCTU	Actual Offering Cost ActualOfferingCost	741628	usd
CY2023Q2	USCTU	Class Ordinary Shares ClassOrdinaryShares	4312500	shares
CY2023Q2	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	8062500	shares
CY2023Q2	us-gaap	Share Price SharePrice	1.00
CY2024Q3	USCTU	Outstanding Invoice OutstandingInvoice	31000	usd
CY2024Q3	USCTU	Pay Certain Liabilities PayCertainLiabilities	300000	usd
CY2024Q3	USCTU	Loan Loan	60000	usd
CY2021Q4	us-gaap	Proceeds From Repayments Of Notes Payable ProceedsFromRepaymentsOfNotesPayable	300000	usd
CY2021Q4	us-gaap	Notes Payable NotesPayable	279597	usd
CY2021Q4	USCTU	Notes Receivable Related Partie NotesReceivableRelatedPartie	20403	usd
CY2023Q3	USCTU	Promissory Note PromissoryNote	1000000	usd
CY2024Q3	USCTU	Aggregate Principal Amount AggregatePrincipalAmount	2000000	usd
CY2024Q3	us-gaap	Debt Instrument Maturity Date DebtInstrumentMaturityDate	2025-06-30
CY2024Q3	USCTU	Promissory Note Related Party PromissoryNoteRelatedParty	1109412	usd
CY2023Q4	USCTU	Promissory Note Related Party PromissoryNoteRelatedParty	682508	usd
	us-gaap	Payments For Fees PaymentsForFees	0	usd
CY2023	us-gaap	Payments For Fees PaymentsForFees	60000	usd
CY2024Q3	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	0	usd
CY2023Q4	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	0	usd
	USCTU	Related Party Loans Description RelatedPartyLoansDescription	The Working Capital Loans would either be repaid upon consummation of an initial business combination, without interest, or, at the lender’s discretion, up to $1,500,000 of such Working Capital Loans may be convertible into warrants of the post-business combination entity at a price of $1.00 per warrant.
CY2023Q1	USCTU	Aggregate Principal Amount AggregatePrincipalAmount	750000	usd
CY2023Q1	USCTU	Aggregate Principal Amount AggregatePrincipalAmount	250000	usd
CY2023Q1	USCTU	Business Combination Amount BusinessCombinationAmount	375000	usd
CY2023	USCTU	Commitment Fee CommitmentFee	125000	usd
	USCTU	Sponsor Description SponsorDescription	the Sponsor an aggregate of $295,000 to fund the Company’s working capital requirements and the Sponsor agreed to assign to Wejo, effective as of the Closing Date or the earlier termination of the Business Combination Agreement in accordance with its terms or otherwise, an aggregate of 83,250 Founder Shares and 250,000 Private Warrants. Wejo paid $250,000 to the Sponsor on January 11, 2023 and $45,000 to the Sponsor on March 2, 2023, for an aggregate payment of $295,000.
CY2024Q3	USCTU	Working Capital WorkingCapital	250000	usd
CY2023Q1	USCTU	Fair Value Of Founder Shares FairValueOfFounderShares	83250	shares
CY2023Q1	USCTU	Fair Value Of Founder Shares Value FairValueOfFounderSharesValue	294289	usd
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	1.0788	pure
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0478	pure
CY2023Q1	USCTU	Closing Price ClosingPrice	0.03
	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	6789	usd
CY2023Q3	USCTU	Sponsor Contribution SponsorContribution	0	usd
	USCTU	Sponsor Contribution SponsorContribution	250000	usd
CY2024Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	1000000	shares
CY2023Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	1000000	shares
CY2024Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2023Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2024Q3	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2024Q3	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2023Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2023Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2023Q2	USCTU	Remaining Converted Shares RemainingConvertedShares	25000	shares
	USCTU	Share Redemption Price Per Share ShareRedemptionPricePerShare	18.00
CY2021Q4	USCTU	Cash Underwriting Discount CashUnderwritingDiscount	3850000	usd
CY2021Q4	USCTU	Deferred Underwriting Commissions DeferredUnderwritingCommissions	8800000	usd
	USCTU	Deferred Underwriting Commissions DeferredUnderwritingCommissions	8800000	usd
	USCTU	Aggregate Amount Of Underwriting Commissions AggregateAmountOfUnderwritingCommissions	8800000	usd
CY2021Q3	USCTU	Ordinary Shares OrdinaryShares	45000	shares
CY2022Q3	USCTU	Hourly Payment HourlyPayment	125	usd
CY2022Q4	USCTU	Hourly Payment HourlyPayment	125	usd
CY2024Q3	us-gaap	Sponsor Fees SponsorFees	0	usd
	us-gaap	Sponsor Fees SponsorFees	0	usd
CY2024Q3	USCTU	Accounts Payable And Accrued Expenses AccountsPayableAndAccruedExpenses	0	usd
CY2023Q4	USCTU	Accounts Payable And Accrued Expenses AccountsPayableAndAccruedExpenses	0	usd
CY2023Q3	USCTU	Forgiveness Of Debt ForgivenessOfDebt	42181	usd
	us-gaap	Business Combination Acquisition Related Costs BusinessCombinationAcquisitionRelatedCosts	16000	usd
	USCTU	Deferred Legal Fees DeferredLegalFees	0	usd
	USCTU	Deferred Legal Fees DeferredLegalFees	431793	usd
	USCTU	Deferred Legal Fee DeferredLegalFee	0	usd
	USCTU	Deferred Legal Fee DeferredLegalFee	2657577	usd
CY2023Q2	USCTU	Deferred Legal Fees DeferredLegalFees	3730114	usd
CY2023Q2	USCTU	Deferred Legal Fees DeferredLegalFees	3730114	usd
CY2024Q3	USCTU	Overpayment Amount OverpaymentAmount	147410	usd
CY2024Q3	USCTU	Trust Account Receivable TrustAccountReceivable	0	usd
CY2024Q3	USCTU	Fair Value Price Per Warrant FairValuePricePerWarrant	0.0012
CY2023Q4	USCTU	Fair Value Price Per Warrant FairValuePricePerWarrant	0.03

Files In Submission

Name	View Source	Status
0001829126-24-007532-index-headers.html	Edgar Link	pending
0001829126-24-007532-index.html	Edgar Link	pending
0001829126-24-007532.txt	Edgar Link	pending
0001829126-24-007532-xbrl.zip	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
rothchacq_10q.htm	Edgar Link	pending
rothchacq_ex31-1.htm	Edgar Link	pending
rothchacq_ex31-2.htm	Edgar Link	pending
rothchacq_ex31-3.htm	Edgar Link	pending
rothchacq_ex32-1.htm	Edgar Link	pending
rothchacq_ex32-2.htm	Edgar Link	pending
rothchacq_ex32-3.htm	Edgar Link	pending
Show.js	Edgar Link	pending
usctu-20240930.xsd	Edgar Link	pending
usctu-20240930_cal.xml	Edgar Link	unprocessable
usctu-20240930_def.xml	Edgar Link	unprocessable
usctu-20240930_pre.xml	Edgar Link	unprocessable
usctu-20240930_lab.xml	Edgar Link	unprocessable
rothchacq_10q_htm.xml	Edgar Link	completed

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$USCTF
Roth CH Acquisition Co. Stock $usctf

2024 Q3 Form 10-Q Financial Statement

#000182912624007532 Filed on November 14, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$USCTF Roth CH Acquisition Co. Stock $usctf

2024 Q3 Form 10-Q Financial Statement

#000182912624007532 Filed on November 14, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$USCTF
Roth CH Acquisition Co. Stock $usctf